Processa Pharmaceuticals (PCSA) Common Equity (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Common Equity came in at $2.5 million in Q1 2026, down 27.95% YoY from $3.5 million in Q1 2025, and down 54.44% on a QoQ basis from $5.6 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Common Equity (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Common Equity data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Common Equity fell 27.95% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 27.95% YoY) and the FY2025 annual result came in at $5.6 million, up 228.82% from the prior year.
- Common Equity slipped to $2.5 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $23.2 million in Q1 2022 to a low of $1.7 million in Q4 2024.
- A 5-year average of $8.4 million and a median of $6.1 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity plunged 70.69% — and 2025, when it surged 228.82%.
- Tracing PCSA's Common Equity over 5 years: stood at $7.5 million in 2022, then plunged by 33.22% to $5.0 million in 2023, then slumped by 66.0% to $1.7 million in 2024, then surged by 228.82% to $5.6 million in 2025, then plunged by 54.44% to $2.5 million in 2026.
- The last three Common Equity figures came in at $2.5 million (Q1 2026), $5.6 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -317,341.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 5.58 Mn |
| Sep 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | 6.11 Mn |
| Mar 31, 2025 | 3.53 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 3.72 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Mar 31, 2024 | 8.88 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 9.16 Mn |
| Mar 31, 2023 | 10.14 Mn |
| Dec 31, 2022 | 7.47 Mn |
| Sep 30, 2022 | 17.24 Mn |
| Jun 30, 2022 | 20.08 Mn |
| Mar 31, 2022 | 23.24 Mn |
| Dec 31, 2021 | 25.49 Mn |
| Sep 30, 2021 | 27.21 Mn |
| Jun 30, 2021 | 29.24 Mn |